|Description||Terazosin is a selective alpha 1 antagonist used for treatment of symptoms of prostate enlargement (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.|
|DrugBank||Primary Accession Number: DB01162|
|Type||Approved, Small Molecule|
|Indication||For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.|
|Mechanism of Action||Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia.|
|Absorption||Essentially completely absorbed in man (90% bioavailability).|
|Toxicity||LD50=259.3mg/kg (i.v. in mice)|
You need to load/activate the cURL extension (http://www.php.net/cURL).